{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/dental-abscess/prescribing-information/metronidazole/","result":{"pageContext":{"chapter":{"id":"03d761c0-a760-5547-8910-97a65535bf94","slug":"metronidazole","fullItemName":"Metronidazole","depth":2,"htmlHeader":"<!-- begin field 980d28ac-953c-47b9-808a-a6fe00fe6bdf --><h2>Metronidazole </h2><!-- end field 980d28ac-953c-47b9-808a-a6fe00fe6bdf -->","summary":"","htmlStringContent":"<!-- begin item 0a5a01e0-7c32-4878-9fdb-a6fe00fe6a41 --><!-- end item 0a5a01e0-7c32-4878-9fdb-a6fe00fe6a41 -->","topic":{"id":"d9ce8bcf-6a30-56c3-9028-f291f9b80333","topicId":"7e8f6d78-0b6f-4813-baa8-3184010dd768","topicName":"Dental abscess","slug":"dental-abscess","lastRevised":"Last revised in October 2018","chapters":[{"id":"82801101-5e68-547d-8c3c-4ad6ec3b91b9","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"92e4cbdc-7fa7-574b-bb17-97199587fe2d","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"e4034c8e-5cd0-5dc4-ba1d-f3ca1fe09c21","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"84291395-fd80-58ef-a144-855cbf9b7b46","slug":"changes","fullItemName":"Changes"},{"id":"07b47e29-f600-5771-917c-4d6cd9135ed2","slug":"update","fullItemName":"Update"}]},{"id":"e967b353-dcf8-5e71-a9b0-95ca162918b8","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"244fc23b-f275-5565-b50c-dca750baa8d9","slug":"goals","fullItemName":"Goals"},{"id":"1eb55d27-8795-5d81-8b81-4b4b6b7efa18","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"2423d7f3-a323-50a3-8bbd-9664897bccd4","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"f5780547-92b5-5ede-a620-c7cf34a41b3b","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"e9cfdeb1-ec38-5e0d-b03e-0acd118058b8","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"fa0115e4-0051-5374-8fae-1e1fbec27b97","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"5f20011b-3e94-5351-a2a6-2a9565c42d7a","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"69b7a1cd-7d22-52ab-b602-3a0c4bfbb4d4","slug":"definition","fullItemName":"Definition"},{"id":"617d13f2-34cd-5fd2-8869-198c3a3d5f06","slug":"causes","fullItemName":"Causes"},{"id":"777f9b6b-175c-5308-bba6-916d89e075b3","slug":"prevalence","fullItemName":"Prevalence"},{"id":"cf5def0d-1ffd-5d57-b788-273fc8248d5c","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"735fc661-47ce-5a94-a29f-f0076c17ce88","slug":"complications","fullItemName":"Complications"}]},{"id":"df647f07-2727-5ac9-b87c-5adcdcf79bd6","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"b2a41850-a8dc-5b90-a7c5-4f2216c54cd2","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"d97daa33-59c0-5607-a1fe-03238b7b333f","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"6b0a689b-1ec7-5794-a5f0-b4efc84acfd2","fullItemName":"Management","slug":"management","subChapters":[{"id":"e6487762-ae28-5710-865a-01603c95176a","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"86cee72a-afc7-5150-92f0-6ff0e90b0172","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"a9ed2df0-8168-51d7-b8e8-f5bb7c662d36","slug":"analgesics","fullItemName":"Analgesics"},{"id":"c8a5d71d-6f87-5315-aa1f-59791511dafe","slug":"amoxicillin","fullItemName":"Amoxicillin"},{"id":"9bd34406-b8a3-5ab1-8a5d-3bd78925ef32","slug":"clarithromycin","fullItemName":"Clarithromycin"},{"id":"03d761c0-a760-5547-8910-97a65535bf94","slug":"metronidazole","fullItemName":"Metronidazole"},{"id":"91946ef3-8703-52eb-ba0a-b9cabca622e5","slug":"phenoxymethylpenicillin","fullItemName":"Phenoxymethylpenicillin"}]},{"id":"9c1469e7-dbca-5eaa-b2cd-29e127addf9a","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"aac7c7e4-eb79-5922-8ea7-3250adfae6b3","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"5aabd034-b3df-5bf4-93c1-30787cb35e17","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"6420441b-a18d-5bdb-a114-17409f623a23","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"65e26e16-4508-5e81-a8bf-307836e310cd","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"0aba46be-7078-5b8a-8557-56574cc69291","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"2d089d7b-e753-518e-95f6-04243be55427","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"f724f89d-9d85-5d8b-9675-d551cbf4aa5e","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"86cee72a-afc7-5150-92f0-6ff0e90b0172","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"a18b43cb-932b-5aa9-a630-991e41ec3fe3","slug":"dose","fullItemName":"Dose","depth":3,"htmlHeader":"<!-- begin field eb60c2a2-7f6e-4b4d-b7e7-a71900eff593 --><h3>What dose of metronidazole should I prescribe?</h3><!-- end field eb60c2a2-7f6e-4b4d-b7e7-a71900eff593 -->","summary":"","htmlStringContent":"<!-- begin item 0030c1c1-4236-434f-ae36-a71900eff628 --><!-- begin field cd26349c-ca2a-48f5-a83c-a71900eff593 --><ul><li>For dental abscess, prescribe a 5 day course of metronidazole (review after 3 days):<ul><li>Adults: 400 mg three times a day. </li><li>Child 10–18 years of age: 200–250 mg every 8 hours. </li><li>Child 7–10 years of age: 100 mg every 8 hours. </li><li>Child 3–7 years of age: 100 mg every 12 hours. </li><li>Child 1–3 years of age: 50 mg every 8 hours.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/dental-abscess/references/\">BNF 72, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/dental-abscess/references/\">BNF for Children, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/dental-abscess/references/\">PHE, 2017</a>]</p><!-- end field cd26349c-ca2a-48f5-a83c-a71900eff593 --><!-- end item 0030c1c1-4236-434f-ae36-a71900eff628 -->","subChapters":[]},{"id":"c9ef7665-2c11-5a8a-ae25-ff02e8cbab87","slug":"cautions-contraindications","fullItemName":"Cautions and contraindications","depth":3,"htmlHeader":"<!-- begin field 8a23400b-c91b-4be1-96de-a6fe00ff4f38 --><h3>What cautions and contraindications are associated with metronidazole?</h3><!-- end field 8a23400b-c91b-4be1-96de-a6fe00ff4f38 -->","summary":"","htmlStringContent":"<!-- begin item 21bb2dc9-ffc4-43e0-8ba8-a6fe00ff4df0 --><!-- begin field 0fbd676d-37bf-478c-82d1-a6fe00ff4f38 --><ul><li><strong>Do not prescribe metronidazole to a person with:</strong><ul><li>Known metronidazole or nitroimidazole hypersensitivity.</li><li>Cockayne syndrome. Cases of severe hepatotoxicity/acute hepatic failure, including cases with a fatal outcome with very rapid onset after treatment initiation in patients with Cockayne syndrome have been reported with products containing metronidazole for systemic use (oral and suppositories). For people with Cockayne syndrome specialist advice should therefore be sought before prescribing metronidazole.</li></ul></li><li><strong>Prescribe metronidazole with caution </strong><strong>in:</strong><ul><li>People with active or chronic severe peripheral and central nervous system disease as there is a risk of neurological aggravation.</li><li>People with severe liver disease and hepatic encephalopathy due to substantial impairment of metronidazole clearance in the presence of advanced hepatic insufficiency, which may contribute to the symptoms of encephalopathy. One third of the daily dosage may be given once daily.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/dental-abscess/references/\">BNF 72, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/dental-abscess/references/\">ABPI Medicines Compendium, 2017a</a>]</p><!-- end field 0fbd676d-37bf-478c-82d1-a6fe00ff4f38 --><!-- end item 21bb2dc9-ffc4-43e0-8ba8-a6fe00ff4df0 -->","subChapters":[]},{"id":"1f0e240d-a2c8-5013-926c-75b607e5a62a","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field 77821ebf-414c-4209-86fa-a6fe00ff637e --><h3>What are the adverse effects of metronidazole?</h3><!-- end field 77821ebf-414c-4209-86fa-a6fe00ff637e -->","summary":"","htmlStringContent":"<!-- begin item 0c9646e1-1a49-4c69-84de-a6fe00ff62d7 --><!-- begin field 35739be8-2b95-4ecf-a933-a6fe00ff637e --><ul><li><strong>Adverse effects of metronidazole include </strong>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/dental-abscess/references/\">BNF 72, 2016</a>]<strong>: </strong> <ul><li>Gastro-intestinal disturbances including nausea and vomiting, anorexia, very rarely hepatitis, jaundice, pancreatitis.</li><li>Taste disturbances, furred tongue, oral mucositis.</li><li>Headache, ataxia.</li><li>Thrombocytopenia, pancytopenia. </li><li>Myalgia, arthralgia.</li><li>Darkening of urine.</li><li>Rash, pruritus, and erythema multiforme.</li></ul></li><li>Warn people taking metronidazole about the potential for drowsiness, dizziness, confusion, hallucinations, convulsions or transient visual disorders. Advise them not to drive or operate machinery if these symptoms occur [<a class=\"bibliography-reference internal-reference\" href=\"/topics/dental-abscess/references/\">ABPI Medicines Compendium, 2017a</a>]. </li><li>Severe bullous skin reactions such as Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN) or acute generalised exanthematous pustulosis (AGEP) have been reported. If symptoms/signs are present, treatment must be immediately discontinued.</li></ul><!-- end field 35739be8-2b95-4ecf-a933-a6fe00ff637e --><!-- end item 0c9646e1-1a49-4c69-84de-a6fe00ff62d7 -->","subChapters":[]},{"id":"fd81a4bc-785a-5297-b2d9-2efa1bbe1400","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field 1853bdf5-9e60-457d-a782-a6fe00ff776d --><h3>What are the important drug interactions with metronidazole?</h3><!-- end field 1853bdf5-9e60-457d-a782-a6fe00ff776d -->","summary":"","htmlStringContent":"<!-- begin item 579c8a56-512b-48fa-89a6-a6fe00ff76cd --><!-- begin field 786afa0f-b5f2-41c4-865e-a6fe00ff776d --><ul><li><strong>Important drug interactions associated with metronidazole include: </strong><ul><li><strong>Alcohol </strong>— some people taking oral metronidazole experience a disulfiram-like reaction with alcohol [<a class=\"bibliography-reference internal-reference\" href=\"/topics/dental-abscess/references/\">BNF 72, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/dental-abscess/references/\">ABPI Medicines Compendium, 2017a</a>].<ul><li>Warn the person that they <em>might </em>experience this reaction if they drink alcohol whilst on metronidazole and for at least 48 hours afterwards [<a class=\"bibliography-reference internal-reference\" href=\"/topics/dental-abscess/references/\">ABPI Medicines Compendium, 2017a</a>]. </li></ul></li><li><strong>Anticoagulants </strong>— the anticoagulant effects of warfarin can be markedly increased by metronidazole [<a class=\"bibliography-reference internal-reference\" href=\"/topics/dental-abscess/references/\">Preston, 2016</a>]. <ul><li>Monitor the international normalized ratio (INR) if metronidazole is given with warfarin and adjust the warfarin dose accordingly. </li></ul></li><li><strong>Ciclosporin </strong>— when co-administration of metronidazole and ciclosporin are necessary, serum ciclosporin levels and serum creatinine should be closely monitored [<a class=\"bibliography-reference internal-reference\" href=\"/topics/dental-abscess/references/\">ABPI Medicines Compendium, 2017a</a>].</li><li><strong>Lithium </strong>— seek specialist advice regarding the use of metronidazole with lithium, as lithium dose reduction may be required due to the risk of renal damage with concurrent use. Plasma concentrations of lithium, creatinine, and electrolytes should be monitored if metronidazole and lithium are used simultaneously [<a class=\"bibliography-reference internal-reference\" href=\"/topics/dental-abscess/references/\">ABPI Medicines Compendium, 2017a</a>].</li></ul></li><li>Additional contraceptive precautions are <em>not </em>required during or after courses of metronidazole [<a class=\"bibliography-reference internal-reference\" href=\"/topics/dental-abscess/references/\">FSRH, 2011</a>]. However, advise women on the importance of correct contraceptive practice if they experience vomiting or diarrhoea. For further information, see the section on vomiting or diarrhoea in the CKS topics on <a class=\"topic-reference external-reference\" href=\"/topics/contraception-combined-hormonal-methods/\">Contraception - combined hormonal methods</a> and <a class=\"topic-reference external-reference\" href=\"/topics/contraception-progestogen-only-methods/\">Contraception - progestogen-only methods</a>.</li></ul><!-- end field 786afa0f-b5f2-41c4-865e-a6fe00ff776d --><!-- end item 579c8a56-512b-48fa-89a6-a6fe00ff76cd -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}